Related references
Note: Only part of the references are listed.A Randomized Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Recombinant Erwinia Asparaginase (JZP-458) in Healthy Adult Volunteers
Tong Lin et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2021)
Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group
Sumit Gupta et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A single-center multidisciplinary approach to managing the global Erwinia asparaginase shortage
Bernard L. Marini et al.
LEUKEMIA & LYMPHOMA (2019)
Universal premedication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions
Stacy L. Cooper et al.
PEDIATRIC BLOOD & CANCER (2019)
Incidence of Hypersensitivity Reactions (HSR) Reactions (HSR) to Peg-Asparaginase (PEG-ASP) in 6136 Patients Treated in the AIEOP-BFM ALL 2009 Study Protocol
Carmelo Rizzari et al.
BLOOD (2019)
Development of L-Asparaginase Biobetters: Current Research Status and Review of the Desirable Quality Profiles
Larissa Pereira Brumano et al.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2019)
Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses
Patrick W. Burke et al.
LEUKEMIA RESEARCH (2018)
Efficacy and safety of recombinant E-coli asparaginase in children with previously untreated acute lymphoblastic leukemia: A randomized multicenter study of the Dutch Childhood Oncology Group
Inge M. van der Sluis et al.
PEDIATRIC BLOOD & CANCER (2018)
Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia
Lynda M. Vrooman et al.
PEDIATRIC BLOOD & CANCER (2016)
Half-Life Extension of Biopharmaceuticals using Chemical Methods: Alternatives to PEGylation
Soren B. van Witteloostuijn et al.
CHEMMEDCHEM (2016)
Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation
Inge M. van der Sluis et al.
HAEMATOLOGICA (2016)
Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation
Inge M. van der Sluis et al.
HAEMATOLOGICA (2016)
L-asparaginase in the treatment of patients with acute lymphoblastic leukemia
Rachel A. Egler et al.
JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS (2016)
Acute lymphoblastic leukemia: an assessment of international incidence, survival, and disease burden
Aaron J. Katz et al.
CANCER CAUSES & CONTROL (2015)
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
Ching-Hon Pui et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
PEG-Asparaginase Allergy in Children With Acute Lymphoblastic Leukemia in the NOPHO ALL2008 Protocol
Louise Tram Henriksen et al.
PEDIATRIC BLOOD & CANCER (2015)
Recombinant protein expression in Escherichia coli: advances and challenges
German L. Rosano et al.
FRONTIERS IN MICROBIOLOGY (2014)
Validation of a 30-year-old process for the manufacture of l-asparaginase from Erwinia chrysanthemi
David Gervais et al.
BIOPROCESS AND BIOSYSTEMS ENGINEERING (2013)
Efficacy and safety of recombinant E. coli-asparaginase in infants (less than one year of age) with acute lymphoblastic leukemia
Inge van der Sluis et al.
HAEMATOLOGICA (2013)
L-Asparaginase Treatment in Acute Lymphoblastic Leukemia
Rob Pieters et al.
CANCER (2011)
Erwinia Asparaginase After Allergy to E. coli Asparaginase in Children With Acute Lymphoblastic Leukemia
Lynda M. Vrooman et al.
PEDIATRIC BLOOD & CANCER (2010)
Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial
Rob Pieters et al.
BLOOD (2008)
Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study
I. M. Appel et al.
LEUKEMIA (2008)
Allergic reactions to E-coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia -: A Children's Oncology Group study
Pierre Wacker et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2007)
Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia
A Pession et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Advanced genetic strategies for recombinant protein expression in Escherichia coli
HP Sorensen et al.
JOURNAL OF BIOTECHNOLOGY (2005)
Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients
B Wang et al.
LEUKEMIA (2003)
Share Paper
